A Pilot Study to Evaluate the PhageTech Virus BioResistor inDetecting Combinations of Bladder Cancer Biomarkers inPatients Under Active BCa Surveillance


  • Org Study ID: VBRm BCA-01
  • Secondary ID: N/A
  • NCT ID: NCT04756284
  • Sponsor: PhageTech, Inc.


To evaluate the effectiveness of the PhageTech Virus BioResistor to detect bladder cancer biomarkers.


This study will sample urine provided by bladder cancer patients as part of their normal routine surveillance screening. No additional effort will be required from the patients and only modest additional effort from the study staff. Some de-identified patient medical information may also be requested, including concominant medications, relevant current or previous diseases, prior bladder cancer interventions and other relevant information to ensure there are no interfering substances or other confounders that could affect study results. There is no risk to patients as the normal diagnostics for bladder cancer will be followed.

  • Overall Status
    Unknown status
  • Start Date
    February 8, 2021
  • Phase
  • Study Type


Primary Outcome 1 - Measure:

Primary Outcome 1 - Timeframe: N/A


  • Bladder Cancer


Inclusion Criteria:
1. Male and female patients ≥ 18 years

- 2. Previous bladder cancer diagnosis; any stage and histological type, undergoing cystoscopy

- 3. Patients with suspected bladder tumor undergoing surveillance cystoscopy

- 4. Patients must provide written Informed Consent.
Exclusion Criteria:
1. Patients unable or unwilling to sign the informed consent

- 2. Age < 18 years - 3. Known HIV/HCV/HBV (information from clinical history).

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No


Name: N/A

Role: N/A

Affiliation: N/A

Overall Contact

Name: Rodney Brenneman

Phone: 949-433-6007

Email: rbrenneman@phagetech.com


Facility Status Contact